Clayton et al., 2013 - Google Patents
Malignant tumors with clear cell morphology: a comparative immunohistochemical study with renal cell carcinoma antibody, Pax8, steroidogenic factor 1, and …Clayton et al., 2013
- Document ID
- 13035083557738113606
- Author
- Clayton E
- Ziober A
- Yao Y
- Bing Z
- Publication year
- Publication venue
- Annals of Diagnostic Pathology
External Links
Snippet
This study aimed to identify an immunohistochemical panel to aid in the differential diagnosis for tumors with clear cell morphology. Twenty-five clear cell renal cell carcinomas (CCRCCs), 19 clear cell ovarian carcinoma (CCOCs), 20 cases of adrenal cortical …
- 101700082182 PAX8 0 title abstract description 54
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Berg et al. | SATB2 as an immunohistochemical marker for colorectal adenocarcinoma: a concise review of benefits and pitfalls | |
Gulmann et al. | Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract | |
Miyamoto et al. | GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor | |
Yamashita et al. | Napsin A is a specific marker for ovarian clear cell adenocarcinoma | |
Rogers et al. | Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy | |
Chang et al. | Use of PAX8 and GATA3 in diagnosing sarcomatoid renal cell carcinoma and sarcomatoid urothelial carcinoma | |
Lee et al. | Prognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers | |
Van Zijl et al. | Epithelial–mesenchymal transition in hepatocellular carcinoma | |
Weissferdt et al. | Comparative immunohistochemical analysis of pulmonary and thymic neuroendocrine carcinomas using PAX8 and TTF-1 | |
Oh et al. | Prognostic impact of fascin-1 expression is more significant in advanced colorectal cancer | |
Zhou et al. | Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials | |
Xue et al. | Non-ampullary–duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas | |
Jethon et al. | Prognostic significance of SOX18 expression in non-small cell lung cancer | |
Ronnett | Endocervical adenocarcinoma: selected diagnostic challenges | |
Qin et al. | Expression and significance of homeodomain protein Cdx2 in gastric carcinoma and precancerous lesions | |
Wang et al. | Clinicopathological characteristics and prognosis of alpha-fetoprotein positive gastric cancer in Chinese patients | |
Chang et al. | The prognostic significance of nuclear CSE1L in urinary bladder urothelial carcinomas | |
Agarwal et al. | Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma | |
Clayton et al. | Malignant tumors with clear cell morphology: a comparative immunohistochemical study with renal cell carcinoma antibody, Pax8, steroidogenic factor 1, and brachyury | |
Huang et al. | Novel markers of squamous differentiation in the urinary bladder | |
Zhou et al. | Expression and clinical significance of galectin-3 in osteosarcoma | |
Nazarian et al. | Cytokeratin 17: an adjunctive marker of invasion in squamous neoplastic lesions of the anus | |
Chen et al. | FGFR4 and TGF-β1 expression in hepatocellular carcinoma: correlation with clinicopathological features and prognosis | |
Xu et al. | Analysis of clinical characteristics and differential diagnosis of the lung biopsy specimens in 99 adenocarcinoma cases and 111 squamous cell carcinoma cases: Utility of an immunohistochemical panel containing CK5/6, CK34βE12, p63, CK7 and TTF-1 | |
Hechtman et al. | Promyelocytic leukemia zinc finger and histone H1. 5 differentially stain low-and high-grade pulmonary neuroendocrine tumors: a pilot immunohistochemical study |